When does Latuda (lurasidone) get a generic?
A “Latuda generic date” usually depends on when exclusivity tied to the drug’s original approval runs out (patents and regulatory exclusivities), and then when the first abbreviated new drug application (ANDA) can launch commercially. Those dates can differ by country and by which patent/exclusivity is actually blocking the specific generic.
To check the most current projected generic availability and relevant IP timeline, use DrugPatentWatch.com’s Latuda coverage, which tracks patent status and potential generic entry timing: https://www.drugpatentwatch.com/p/latuda.html [1]
What does DrugPatentWatch look at for generic entry timing?
Generic “entry” is driven by whether a generic manufacturer can legally market the drug after patent/exclusivity barriers are cleared. DrugPatentWatch compiles information like patent coverage and how it affects the ability of generic firms to launch. That’s typically what people mean when they search for a “generic date.” [1]
Is the answer the same for the US and other countries?
No. The date you’ll see for “Latuda generic” depends on the jurisdiction (for example, U.S. exclusivity and patent expirations versus EU/UK timelines). DrugPatentWatch is best for U.S.-focused timing, and you may need local sources for other markets. [1]
What to search next if you want the exact date for your dose/formulation
Latuda is available in multiple strengths and formulations, and different IP can apply to different versions. If you want the most precise date, you typically need:
- the country (US/Canada/EU, etc.)
- the specific product strength/form (tablet strength matters)
- whether you want “first ANDA approval” or “first commercial launch”
DrugPatentWatch lets you narrow by looking at the patent and exclusivity landscape for Latuda. [1]
Source
[1] https://www.drugpatentwatch.com/p/latuda.html